Evidence map›Paper›PMID 24845061›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2014

(+)-2-(1-Hydroxyl-4-oxocyclohexyl) ethyl caffeate suppresses solar UV-induced skin carcinogenesis by targeting PI3K, ERK1/2, and p38.

Do Young Lim, Mee-Hyun Lee, Seung Ho Shin, Hanyoung Chen, Joohyun Ryu, Lei Shan, Honglin Li, Ann M Bode, Wei-Dong Zhang, Zigang Dong

Open access · greenAbstract read
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Do Young LimThe Hormel Institute, University of Minnesota, Austin, Minnesota;
Mee-Hyun LeeThe Hormel Institute, University of Minnesota, Austin, Minnesota;
Seung Ho ShinThe Hormel Institute, University of Minnesota, Austin, Minnesota; Program in Biomedical Informatics and Computational Biology, University of Minnesota, Minneapolis, Minnesota.
Hanyoung ChenThe Hormel Institute, University of Minnesota, Austin, Minnesota;
Joohyun RyuThe Hormel Institute, University of Minnesota, Austin, Minnesota;
Lei ShanDepartment of Natural Product Chemistry, Second Military Medical University;
Honglin LiSchool of Pharmacy, East China University of Science & Technology, Shanghai, PR China; and.
Ann M BodeThe Hormel Institute, University of Minnesota, Austin, Minnesota;
Wei-Dong ZhangDepartment of Natural Product Chemistry, Second Military Medical University; zgdong@hi.umn.edu wdzhangy@hotmail.com.
Zigang DongThe Hormel Institute, University of Minnesota, Austin, Minnesota; zgdong@hi.umn.edu wdzhangy@hotmail.com.
University of Minnesota · USHormel (United States) · USSecond Military Medical University · CNEast China University of Science and Technology · CN

Funding

VITAMIN A, AND ITS PRECURSORS AND DERIVATIVES AS THERAPEUTIC MODALITIESP01CA027502 · NCI · UNIVERSITY OF ARIZONA · PI EINSPAHR, JANINE G · 1985 to 2015
$36.3M
The role of histone phosphorylation in arsenic-induced cell transformation and skR01ES016548 · NIEHS · UNIVERSITY OF MINNESOTA · PI DONG, ZIGANG · 2008 to 2012
$1.7M
Developing new ornithine decarboxylase inhibitors to prevent skin & colon cancerR01CA166011 · NCI · UNIVERSITY OF MINNESOTA · PI DONG, ZIGANG · 2013 to 2017
$1.6M
Anticarcinogenic Mechanisms of Tea ConstituentsR37CA081064 · NCI · UNIVERSITY OF MINNESOTA · PI DONG, ZIGANG · 2008 to 2012
$1.5M
Molecular Mechanisms and Targets of Soy Compounds in the Prevention of Colon CancR21CA172457 · NCI · UNIVERSITY OF MINNESOTA · PI DONG, ZIGANG · 2013 to 2014
$327k
NCI NIH HHS CA027502NCI NIH HHS CA166011NCI NIH HHS CA172457NCI NIH HHS P01 CA027502NCI NIH HHS R01 CA166011NCI NIH HHS R21 CA172457NCI NIH HHS R37 CA081064NIEHS NIH HHS ES016548NIEHS NIH HHS R01 ES016548
6 · The paper itself

Abstract

For decades, skin cancer incidence has increased, mainly because of oncogenic signaling pathways activated by solar ultraviolet (UV) irradiation (i.e., sun exposure). Solar UV induces multiple signaling pathways that are critical in the development of skin cancer, and therefore the development of compounds capable of targeting multiple molecules for chemoprevention of skin carcinogenesis is urgently needed. Herein, we examined the chemopreventive effects and the molecular mechanism of (+)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeate (HOEC), isolated from Incarvillea mairei var. grandiflora (Wehrhahn) Grierson. HOEC strongly inhibited neoplastic transformation of JB6 Cl41 cells without toxicity. PI3K, ERK1/2, and p38 kinase activities were suppressed by direct binding with HOEC in vitro. Our in silico docking data showed that HOEC binds at the ATP-binding site of each kinase. The inhibition of solar UV-induced PI3K, ERK1/2, and p38 kinase activities resulted in suppression of their downstream signaling pathways and AP1 and NF-κB transactivation in JB6 cells. Furthermore, topical application of HOEC reduced skin cancer incidence and tumor volume in SKH-1 hairless mice chronically exposed to solar UV. In summary, our results show that HOEC exerts inhibitory effects on multiple kinase targets and their downstream pathways activated by solar UV in vitro and in vivo. These findings suggest that HOEC is a potent chemopreventive compound against skin carcinogenesis caused by solar UV exposure.

Indexed as

Adenosine TriphosphateAdministration, TopicalAnimalsAnticarcinogenic AgentsBinding, CompetitiveBinding SitesCaffeic AcidsCell LineCell ProliferationCyclohexanonesEpidermisExtracellular Signal-Regulated MAP KinasesFemaleGene Expression Regulation, EnzymologicMicep38 Mitogen-Activated Protein Kinases2-(1-hydroxy-4-oxocyclohexyl)ethyl caffeateAdenosine TriphosphateAnticarcinogenic AgentsCaffeic AcidsCyclohexanonesethyl caffeateExtracellular Signal-Regulated MAP Kinasesp38 Mitogen-Activated Protein KinasesPhosphatidylinositol 3-KinasesPlant Extracts

Identifiers

PMID24845061
PMCPMC4125463
OpenAlexW2324420458

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.